Overview

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Status:
Terminated
Trial end date:
2019-08-06
Target enrollment:
Participant gender:
Summary
This main study objective was to evaluate the safety and tolerability of intravenous (IV) SYNT001 (ALXN1830) in participants with WAIHA.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Alexion Pharmaceuticals
Syntimmune, Inc.